Key takeaways
Ubrelvy (ubrogepant) and Ajovy (fremanezumab) are both medications used to manage migraines, but they have different purposes and methods of administration. Ubrelvy is an oral medication used to treat sudden migraine attacks in adults, while Ajovy is an injectable medication used to prevent migraines. Both medications belong to the calcitonin gene-related peptide (CGRP) receptor blocker class, but Ubrelvy is taken as needed, with a maximum of two doses per day, whereas Ajovy is administered once a month or once every three months. Both medications are available only as brand-name products. Ubrelvy can cause side effects like nausea, sleepiness, and dry mouth, while Ajovy may cause injection site reactions such as pain, swelling, and redness. Ubrelvy interacts with many medications, including certain antibiotics and seizure medications, while Ajovy has fewer interactions but has a potential for allergic reactions. Additionally, Ubrelvy can be taken with or without food, but a high-fat meal may delay its effectiveness, and Ajovy requires proper storage and handling due to its injectable form.
